As of Nov 19, 2026, 0 of 2 active firms rate LFCR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LFCR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.30 – $-0.27 · 3 analysts · -34% YoY
Next period, 3 analysts expect Lifecore Biomedical Inc. to earn $-0.28 a share (range $-0.30 – $-0.27), versus $-0.43 a year earlier. Full-year consensus is $-1.83, growing to $-0.88 the year after.
REVENUE · NEXT QUARTER
$27.1M
Range $25.4M – $29.6M · 3 analysts · +17% YoY
Revenue is expected to reach $27.1M (range $25.4M – $29.6M), +16.7% year-over-year. Full-year consensus is $120.4M, rising to $131.0M next year.
Top analysts covering Lifecore Biomedical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LFCR.
#1
Paul Knight
Keybanc · Rank #394
Neutral
No targeton LFCR
Overall win rate
39%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #452
Neutral
No targeton LFCR
Overall win rate
32%
+ Follow
#3
MS
Max Smock
William Blair
Neutral
No targeton LFCR
Coverage
—
+ Follow
#4
SE
Steven Etoch
Stephens & Co.
Neutral
$5.00-21.9% to target
Coverage
—
+ Follow
LFCR stock forecast FAQ
What is LFCR's average 12-month price target?+
The 1 active firms with a live target average $6.50 for Lifecore Biomedical Inc. over the next 12 months, ranging from a $6.50 high to a $6.50 low, as of Nov 19, 2026.
Is LFCR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover LFCR?+
2 active firms have a recognized rating on Lifecore Biomedical Inc. as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LFCR?+
Among analysts who currently cover LFCR, Paul Knight of Keybanc has the strongest overall Quantellect track record (Rank #394). Their current call is Neutral.
What is Lifecore Biomedical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.30 – $-0.27) across 3 analysts. Full-year EPS is projected at $-1.83, rising to $-0.88 the following year.
How much revenue is Lifecore Biomedical Inc. expected to report next quarter?+
Consensus revenue is $27.1M (range $25.4M – $29.6M). Full-year revenue is projected at $120.4M, growing to $131.0M next year.
Have analysts been upgrading or downgrading LFCR lately?+
As of Nov 19, 2026, 0 of 2 active firms rate LFCR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LFCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.